Skip to main content
BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%
Pricing
Get started→
macroJul 31, 2026, 11:23 AM

Novo Nordisk: ZEUS Outcome Won't Affect 2026 Profit Outlook

Novo Nordisk says the ZEUS trial outcome will not alter its previously communicated adjusted operating profit guidance for 2026, though it will lead to a non-cash impairment charge in Q3 2026.

NVO

Novo Nordisk has clarified that results from the ZEUS program will have no effect on its adjusted operating profit outlook for 2026. The company had previously communicated this forecast.

Instead, the outcome will trigger a non-cash impairment charge in the third quarter of 2026. No further details about the size of the impairment or the nature of the ZEUS program were immediately provided.

Source: First Squawk